Examine the Possible Association of Hepatic CYP3A Activity and the Susceptibility to Femur Head Necrosis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00244400

Enrollment

200

Registered

2005-10-26

Start date

2002-11-30

Completion date

2006-01-31

Last updated

2006-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Femur Head Necrosis

Keywords

Femur Head Necrosis, CYP3A

Brief summary

The purpose of the present study was to examine the possible association of hepatic CYP3A activity and the susceptibility to femur head necrosis in patients treated with corticosteroids.

Detailed description

Femur head necrosis is one of the major side effects of corticosteroid therapy. Since corticosteroids are metabolized by hepatic cytochrome P-450 (CYP) 3A, a low endogenous activity of this enzyme may contribute to the pathogenesis of ONFH. The purpose of the present study was to examine the possible association of hepatic CYP3A activity and the susceptibility to femur head necrosis in patients treated with corticosteroids.

Interventions

None listed

Study design

Observational model

DEFINED_POPULATION

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

14 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

* Clinical diagnosis of avascular necrosis of the femur

Exclusion criteria

* Old age (\> 70 years) * Severe hepatic or renal dysfunction * Heart disease * Current use of known CYP3A-inducing or -inhibiting drugs * Morbid obesity

Countries

Japan

Outcome results